Heart Failure

LVAD in Heart Failure Linked to Improved Glycemic Control

LVAD in Heart Failure Linked to Improved Glycemic Control

By

HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.

FDA Fast Track Designation Granted to Praliciguat for HFpEF

FDA Fast Track Designation Granted to Praliciguat for HFpEF

By

The Company is currently enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 trial; they expect to enroll 175 in total.

Outcomes With Rivaroxaban in Chronic Heart Failure With Underlying CAD

Outcomes With Rivaroxaban in Chronic Heart Failure With Underlying CAD

By

Rivaroxaban was not superior to placebo for reducing the rate of death, MI, or stroke in patients with chronic heart failure.

Tafamidis Reduces Mortality, Hospitalizations in Transthyretin Amyloid Cardiomyopathy

Tafamidis Reduces Mortality, Hospitalizations in Transthyretin Amyloid Cardiomyopathy

By

Tafamidis was associated with reduced all-cause mortality and cardiovascular-related complications in patients with transthyretin amyloid cardiomyopathy.

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

By

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes

Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes

By

Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.

Labeling Mix-Up Prompts Recall of HCTZ Bottles That May Contain Another Diuretic

Labeling Mix-Up Prompts Recall of HCTZ Bottles That May Contain Another Diuretic

By

To date, there have been no reports of any adverse events related to this recall.

Emphysema Associated With Worse Outcomes in Heart Failure

Emphysema Associated With Worse Outcomes in Heart Failure

By

After 2.1 years of follow-up, 49% of patients who had emphysema on chest CT were readmitted for heart failure and 24% had died.

Entresto Initiation Soon After Acute HF Episode Safe in HFrEF Patients

Entresto Initiation Soon After Acute HF Episode Safe in HFrEF Patients

By

The Phase 4, randomized, open-label, parallel-group TRANSITION study (N=1002) evaluated the safety and tolerability of Entresto in HFrEF patients after they were stabilized following an acute heart failure episode when treatment was initiated either pre-discharge or post-discharge.

New Clinical Trial Targets Gut Microbiota in Heart Failure

New Clinical Trial Targets Gut Microbiota in Heart Failure

By

GutHeart, a new ongoing clinical trial, will investigate the potential benefits of treating gut bacteria in heart failure.

AHA Issues Scientific Statement on Managing Chagas Cardiomyopathy

AHA Issues Scientific Statement on Managing Chagas Cardiomyopathy

By

The most common findings in patients with Chagas cardiomyopathy include cardiac rhythm abnormalities, myocardial abnormalities, aneurysms, and thromboembolism.

Galafold Approved for the Treatment of Adults With Fabry Disease

Galafold Approved for the Treatment of Adults With Fabry Disease

By

The FDA has approved Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease.

Kapspargo Sprinkle Available to Treat Hypertension, Angina, Heart Failure

Kapspargo Sprinkle Available to Treat Hypertension, Angina, Heart Failure

By

For patients unable to swallow an intact capsule, the pellets can be sprinkled over soft food (eg, applesauce, yogurt, pudding) or given via a nasogastric (NG) tube.

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

By

There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.

AHA Introduces Heart Failure Certification Program

AHA Introduces Heart Failure Certification Program

The advanced certification program promotes heart failure management and implementation of clinical practice guidelines.

Which Drugs Are Effective for Preventing Sudden Cardiac Death in HFrEF?

Which Drugs Are Effective for Preventing Sudden Cardiac Death in HFrEF?

By

For this study, researchers searched multiple databases for studies in which the effectiveness of various pharmacologic interventions were evaluated in patients with HFrEF.

Rapid Improvement of Dilated Cardiomyopathy With Anakinra

Rapid Improvement of Dilated Cardiomyopathy With Anakinra

The patient's clinical symptoms related to heart failure improved markedly within 2 weeks of treatment with anakinra.

Protease Inhibitors May Worsen Outcomes for HIV and Heart Failure

Protease Inhibitors May Worsen Outcomes for HIV and Heart Failure

Higher rates seen for hyperlipidemia, diabetes, coronary artery disease, and cardiovascular mortality in patients who received protease inhibitors.

Heart Failure Risk Increased in ALVSD With Diabetes

Heart Failure Risk Increased in ALVSD With Diabetes

Increased risk for heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction.

Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C

Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C

By

HCV viral eradication resulted in improved left ventricular diastolic dysfunction.

Portable Sleep Monitoring Accurate in Heart Failure

Portable Sleep Monitoring Accurate in Heart Failure

Respiratory polygraphy can accurately diagnose sleep apnea in patients hospitalized with heart failure.

Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation

Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation

By

Canagliflozin vs other SGLT2 inhibitors and non-SLGT2 inhibitors were examined for the risk for heart failure-related hospitalization and below the knee amputation.

Heart Meds Recalled After Discovery of Possible Carcinogenic Impurity

Heart Meds Recalled After Discovery of Possible Carcinogenic Impurity

By

As valsartan is used to treat various cardiovascular conditions including heart failure and hypertension, patients should continue to take their medications until they have a replacement product,

Heart Failure Risk Increased When Sleep Apnea Not Managed With CPAP

Heart Failure Risk Increased When Sleep Apnea Not Managed With CPAP

By

When sleep apnea was not managed with continuous positive airway pressure, the risk for heart failure increased, regardless of age.

High-Risk <i>APOL1</i> Not Tied to CHD, Stroke in Postmenopausal Black Women

High-Risk APOL1 Not Tied to CHD, Stroke in Postmenopausal Black Women

High-risk APOL1 genotype was linked to HFpEF hospitalization in postmenopausal black women.

Intensified, Multifactorial Intervention for Type 2 Diabetes Reduces Risk for Heart Failure

Intensified, Multifactorial Intervention for Type 2 Diabetes Reduces Risk for Heart Failure

By

Investigators examined the effect of intensified multifactorial intervention on the risk for heart failure-related hospitalization in patients with type 2 diabetes and microalbuminuria.

Clinical Significance of Genetic Variations in CYP2D6 Investigated in HF Patients

Clinical Significance of Genetic Variations in CYP2D6 Investigated in HF Patients

By

According to HF guidelines, beta-blockers must be titrated to a specific target dose in order to obtain their morbidity and mortality benefit in HF patients.

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

By

Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.

Synthetic Cannabis May Increase Ischemic Cardiomyopathy Risk

Synthetic Cannabis May Increase Ischemic Cardiomyopathy Risk

Ischemic cardiomyopathy described in a young man was attributed to synthetic cannabinoid use.

Sign Up for Free e-Newsletters